Print Page   |   Sign In   |   Register
Companies: Myomo, Inc. (MYO)

Company Profile


Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. Based on patented technology developed at MIT, Harvard Medical School, and by the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuro-muscular disability such as amyotrophic lateral sclerosis (“ALS”) or multiple sclerosis (“MS”). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S.

Investment Highlights:

  • Only commercially available upper extremity device
  • Largest home user base in exoskeleton market
  • Attractive gross margins of over 60%
  • Exclusive licensee of MIT developed IP
  • Clear and attainable roadmap to reimbursement code
  • Reduces total cost-of-care
  • Proven management team with exceptional advisors
  • Pre-money valuation of approximately $35 million and the Company has raised over $20 million to date

Myomo, Inc.
One Broadway
14th Flr
Cambridge, MA 02142
Tel: 877-736-9666


TriPoint Global Equities is pleased to announce our latest transaction ( Myomo, Inc. seeks to raise up to $15 million under Regulation A+ of the JOBS Act and then, in succession and subject to New York Stock Exchange (NYSE) requirements, be listed on the NYSE MKT under the ticker “MYO”. Myomo will offer 2,000,000 shares at a price of $7.50 per share, valuing the company at approximately $35 million pre-money. The transaction is expected to close on or about April 20th, 2017. Notably, Myomo is seeking to become the first company to launch a Regulation A+ initial stock offering to be listed on the NYSE.

You may also view the Company’s video presentation, Form 1-A and PPT as well as purchase shares in the IPO, by visiting

Myomo Inc.’s offering statement for its initial public offering under Regulation A has been qualified by the Securities and Exchange Commission. The securities offered by Myomo Inc. are highly speculative. Investing in shares of Myomo Inc. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. To obtain a copy of the Offering Circular, go to or click here to download directly 
Community Search
Sign In